Home » Pfizer Action to Delay Ranbaxy Lipitor Generic Launch
Pfizer Action to Delay Ranbaxy Lipitor Generic Launch
Indian generics producer Ranbaxy has claimed that it will not proceed with its plans to launch a generic version of Pfizer's blockbuster cholesterol treatment Lipitor (atorvastatin) until related legal issues are resolved.
The company had previously claimed it would press ahead with a launch, despite ongoing legal actions estimated to have cost it some US$25mn last year. Meanwhile, a US ruling is not expected until July, and even if the company succeeds, Pfizer is likely to appeal at the federal level, delaying a possible launch by at least another 12 months.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct